Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Single-dose mRNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Including Alpha and Gamma Variants: A Test-negative Design in Adults 70 Years and Older in British Columbia, Canada

2021; Oxford University Press; Volume: 74; Issue: 7 Linguagem: Inglês

10.1093/cid/ciab616

ISSN

1537-6591

Autores

Danuta M. Skowronski, Solmaz Setayeshgar, Macy Zou, Natalie Prystajecky, John R. Tyson, Eleni Galanis, Monika Naus, David M. Patrick, Hind Sbihi, Shiraz El Adam, Bonnie Henry, Linda Hoang, Manish Sadarangani, Agatha N. Jassem, Mel Krajden,

Tópico(s)

Animal Virus Infections Studies

Resumo

Randomized-controlled trials of messenger RNA (mRNA) vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) included relatively few elderly participants. We assess single-dose mRNA vaccine effectiveness (VE) in adults ≥ 70 years old in British Columbia, Canada, where second doses were deferred by up to 16 weeks and where a spring 2021 wave uniquely included codominant circulation of Alpha (B.1.1.7) and Gamma (P.1) variants of concern (VOC).

Referência(s)